Loading
VM
Vycor Medical Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by FOUNTAINHEAD CAPITAL MANAGEMENT LTD, was filed 06 Jan 2015.
Vycor Medical Inc: what insiders have been doing
Every trade that managers of Vycor Medical Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Nothing new has been filed by managers of Vycor Medical Inc in twelve months, the latest record being from 18 October 2022.
The full history, which starts in 2014, counts 6 purchases against 1 sale. The 10-K for the year ended 31 December 2025 shows 1.9 m USD of revenue and -72,426 USD of net income.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
133
Thresholds
n/a
Buy Volume
€2M
6 ops. · all time
Sell Volume
€12,545
1 ops. · all time
Since the insiders bought
- -52.2%Entry US$1.80 · Close at T+365 US$0.86
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,036 of 26,289 companies
30.7
score / 100
Value22
Quality39
FCF yld-0.8%
Earn yld-3.3%
EV/EBITDA33.3x
ROE·
Gross mgn84%
Net mgn-3.9%
Debt/EBITDA10.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.07
Analyst consensus
Income statement
RevenueUS$1.9M
Gross profitUS$1.6M84% margin
EBITDAUS$96.5k5% margin
Net income-US$72.4k-3.3% margin
Valuation
Beta-0.54
Balance sheet & cash
Market capUS$2.2M
Total debtUS$1M
Free Cash Flow-US$18.7k
Profitability & ownership
ROA3.6%
% insiders61.1%
% institutions0.0%
Last declaration on 18 October 2022
Declarations133 total
535,714 shares@ US$0.10616.8% of flowCommon stockSEC:0001493152-22-028659:0
535,714 shares@ US$0.13820.5% of flowCommon stockSEC:0001493152-22-019121:0
535,714 shares@ US$0.08511.9% of flowCommon stockSEC:0001493152-22-009848:0
535,714 shares@ US$0.09713.0% of flowCommon stockSEC:0001493152-22-001390:0
535,714 shares@ US$0.14419.4% of flowCommon stockSEC:0001493152-21-025019:0
535,714 shares@ US$0.1418.4% of flowCommon stockSEC:0001493152-21-017286:0
33,333 shares@ US$0.214.7% of flowVycor Medical Inc. Common Stock par value $0.001SEC:0001493152-21-008265:0
535,714 shares@ US$0.213.1% of flowCommon stockSEC:0001493152-21-008264:0
33.333 shares@ US$0.210.0% of flowVycor Medical Inc. Common Stock par value $0.0001SEC:0001493152-21-008263:0
33.333 shares@ US$0.210.0% of flowVycor Medical Inc. Common Stock par value $0.0001SEC:0001493152-21-000737:0
535,714 shares@ US$0.213.0% of flowCommon stockSEC:0001493152-21-000733:0
33,333 shares@ US$0.214.5% of flowVycor Medical Inc. Common Stock par value $0.001SEC:0001493152-21-000735:0
535,714 shares@ US$0.2112.9% of flowCommon StockSEC:0001493152-20-019041:0
33,333 shares@ US$0.2124.0% of flowVycor Medical Inc. Common Stock par value $0.0001SEC:0001493152-20-019046:0
33,333 shares@ US$0.2124.1% of flowVycor Medical Inc. Common Stock par value $0.001SEC:0001493152-20-019042:0
33,333 shares@ US$0.2119.9% of flowVycor Medical Inc. Common Stock par value $0.0001SEC:0001493152-20-012775:0
535,714 shares@ US$0.2111.8% of flowCommon StockSEC:0001493152-20-012773:0
33,333 shares@ US$0.2124.7% of flowVycor Medical Inc. Common Stock Par Value $0.0001SEC:0001493152-20-012772:0
33,333 shares@ US$0.2120.0% of flowVycor Medical Inc. Common Stock par value $0.001SEC:0001493152-20-012774:0
33,333 shares@ US$0.2120.2% of flowVycor Medical Inc. Common Stock Par Value $0.0001SEC:0001493152-20-005941:0
33,333 shares@ US$0.2117.1% of flowVycor Medical Inc. Common Stock par value $0.0001SEC:0001493152-20-005944:0
535,714 shares@ US$0.2110.8% of flowCommon StockSEC:0001493152-20-005942:0
33,333 shares@ US$0.2117.0% of flowVycor Medical Inc. Common Stock par value $0.001SEC:0001493152-20-005943:0
33,333 shares@ US$0.2110.1% of flowVycor Medical Inc. Common Stock par value $0.001SEC:0001493152-20-000285:0
535,714 shares@ US$0.217.5% of flowCommon StockSEC:0001493152-20-000283:0
25 of 133 declarations
About Vycor Medical Inc
Vycor Medical Inc. (ticker: VYCO) is a U.S.-based healthcare company headquartered in Boca Raton, Florida, United States. It is currently quoted on the OTCQB rather than the NYSE or NASDAQ, but it remains relevant for investors following U.S. medical-device microcaps and SEC filing activity, including insider transactions reported on Form 4.
The company was formed in 2005 as Vycor Medical LLC and later converted into a Delaware corporation in 2007. From inception, Vycor has pursued a highly specialized strategy focused on neurosurgical access and neuro-therapeutic solutions. Its business is organized around two operating units. The first, Vycor Medical, commercializes the ViewSite™ Brain Access System (VBAS), a disposable cranial access platform designed for neurosurgery. The second, NovaVision®, is a development-stage business offering therapy programs intended to help patients recover visual function after stroke or brain injury.
Read moreShow less
Vycor’s market position is that of a niche specialty device company rather than a broad-based medtech platform. In this segment, clinical credibility matters as much as commercial execution. The company has emphasized a growing body of peer-reviewed publications supporting VBAS, which can be important for surgeon adoption, hospital procurement discussions, and credibility in a highly technical market. At the same time, the company remains small and capital-sensitive, with performance tied to product adoption, geographic expansion, and continued progress in development-stage initiatives.
From a geographic standpoint, Vycor’s footprint is still modest, but recent disclosures indicate that growth has been increasingly driven by international markets, while sales in the United States also continue to expand. That suggests the company is gradually building a broader commercial reach beyond its home market, though it is not yet a large global medtech franchise.
Recent company updates point to improving operating trends. In 2025, Vycor reported higher revenues for the Vycor Medical division, with growth largely coming from international markets. It also reported improved operating profitability versus the prior year. The company’s year-end 2025 release continued that pattern, showing further revenue growth and a return to positive operating income at the division level. Those developments are notable for a small-cap medical device issuer because they suggest better operational leverage even as NovaVision remains in development.
For investors, Vycor Medical is best viewed as a focused U.S. healthcare microcap with asymmetric potential: a narrow product portfolio, a specialized clinical niche, and meaningful execution risk. The stock’s characteristics are consistent with a company where regulatory, commercialization, and evidence-generation milestones can matter disproportionately to valuation.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
